Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K.

Nat Genet. 2013 May;45(5):522-525. doi: 10.1038/ng.2583. Epub 2013 Mar 17.

2.

PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).

Sato K, Sakai H, Kato M, Nishio Y, Tsuruoka Y, Uemura Y, Yokoi S, Saito T, Matsunawa M, Suzuki Y, Isobe Y, Inoue Y, Takahashi M, Miura I.

Int J Hematol. 2015 Jun;101(6):608-11. doi: 10.1007/s12185-015-1749-5. Epub 2015 Jan 30.

PMID:
25633778
3.

Chronic myelogenous leukemia with acquired t(11;14)(q13;q32) CCND1-IGH: A case report and literature review.

Manda-Mapalo MT, Khalili P, Quintana D, Rabinowitz I, Zhang QY.

Cancer Genet. 2016 Oct;209(10):481-485. doi: 10.1016/j.cancergen.2016.09.007. Epub 2016 Sep 21.

PMID:
27810077
4.

Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.

Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM; UK Myeloma Forum.

Haematologica. 2009 Dec;94(12):1708-13. doi: 10.3324/haematol.2009.011064.

5.

The t(11;14) (q13;q32) in multiple myeloma cell line KMS12 has its 11q13 breakpoint 330 kb centromeric from the cyclin D1 gene.

Vaandrager JW, Kluin P, Schuuring E.

Blood. 1997 Jan 1;89(1):349-50. No abstract available.

6.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
7.

Derivative (14)t(11;14)(q13;q32)t(11;14)(p11.2;p11.2): a novel unbalanced variant of the t(11;14)(q13;q32) translocation in mantle cell lymphoma.

Sathanoori M, Shekhter-Levin S, Marks SM, Swerdlow SH.

Cancer Genet Cytogenet. 2007 Jan 15;172(2):158-64.

PMID:
17213026
8.

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A.

Am J Pathol. 2000 May;156(5):1505-13.

9.

A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.

Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y, Nakamura S.

Cancer. 1999 Apr 15;85(8):1750-7.

PMID:
10223569
10.

Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).

Guglielmelli T, Giugliano E, Cappia S, Papotti M, Saglio G.

Cancer Genet Cytogenet. 2007 Feb;173(1):51-6.

PMID:
17284370
11.

Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.

Trakhtenbrot L, Hardan I, Koren-Michowitz M, Oren S, Yshoev G, Rechavi G, Nagler A, Amariglio N.

Genes Chromosomes Cancer. 2010 Jan;49(1):17-27. doi: 10.1002/gcc.20716.

PMID:
19787791
12.

Cyclin D1 expression in patients with multiple myeloma.

Troussard X, Avet-Loiseau H, Macro M, Mellerin MP, Malet M, Roussel M, Sola B.

Hematol J. 2000;1(3):181-5.

PMID:
11920187
13.

Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma.

Wlodarska I, Meeus P, Stul M, Thienpont L, Wouters E, Marcelis L, Demuynck H, Rummens JL, Madoe V, Hagemeijer A.

Leukemia. 2004 Oct;18(10):1705-10.

PMID:
15306823
14.

Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Cook JR, Hsi ED, Worley S, Tubbs RR, Hussein M.

Am J Clin Pathol. 2006 Apr;125(4):615-24.

PMID:
16627271
15.

The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ.

Am J Clin Pathol. 2000 Jun;113(6):831-7.

PMID:
10874884
16.

Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.

Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L.

Cancer Genet Cytogenet. 2009 Dec;195(2):164-7. doi: 10.1016/j.cancergencyto.2009.08.013.

PMID:
19963117
17.

Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia.

Avet-Loiseau H, Garand R, Gaillard F, Daviet A, Mellerin MP, Robillard N, Bouyge I, Arcot S, Batzer M, Talmant P, Harousseau JL, Milpied N, Bataille R.

Genes Chromosomes Cancer. 1998 Oct;23(2):175-82.

PMID:
9739021
18.

Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).

Janssen JW, Vaandrager JW, Heuser T, Jauch A, Kluin PM, Geelen E, Bergsagel PL, Kuehl WM, Drexler HG, Otsuki T, Bartram CR, Schuuring E.

Blood. 2000 Apr 15;95(8):2691-8.

19.

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD, Harrington D, Kay NE, Van Ness B, Greipp PR.

Blood. 2002 May 15;99(10):3735-41.

20.

The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization.

Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M.

Blood. 1997 Jul 15;90(2):526-34.

Supplemental Content

Support Center